보고서 요약(국문)

개요
전 세계 위암 치료 시장은 2022년 47억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 8.7%의 성장률을 기록하며 2030년에는 103억 달러에 이를 것으로 예상됩니다.
위암은 위 점막에 악성(암) 세포가 발생하는 질병입니다. 위암은 일반적으로 위 점막을 덮고 있는 점액 생성 세포에서 시작됩니다. 위암의 증상으로는 소화불량, 위 불편감 또는 통증 등이 있습니다. 대부분의 환자는 초기 단계에 증상이 나타나지 않아 진단이 어렵습니다. 이 때문에 위암은 다른 신체 부위로 전이되어 전이성 암이 발생할 때까지 진단되지 않는 경우가 많습니다.
위암은 전 세계적으로 세 번째로 흔한 사망 원인입니다. 미국 국립암연구소(NCI)에 따르면, 암으로 인한 사망의 1.8%가 위암 때문입니다. 미국 암 협회(American Cancer Society)의 2022년 추산에 따르면, 위암은 미국에서 매년 발생하는 모든 신규 암의 약 1.5%를 차지합니다.
또한, 위암 발병률 증가, 좌식 생활 방식과 불규칙한 식습관의 증가, 그리고 종양학 분야의 연구 개발 증가는 향후 시장 성장을 견인할 것으로 예상되는 몇 가지 요인입니다.
시장 동향
신제품 출시 증가
위암은 현재 전 세계적으로 다섯 번째로 흔하게 진단되는 암이며, 네 번째로 흔한 암 관련 사망 원인입니다. 위암 환자의 90~95% 이상이 선암으로 분류됩니다. 미국 암 협회는 2022년에 26,380건의 신규 위암 발병 사례와 11,090명의 사망자를 추산했습니다.
예를 들어, 엔허투(Enhertu)는 2023년 2월 한국에서 위암 3차 치료제를 출시했습니다. 이는 진행성 및 전이성 위암 치료 효과를 향상시키는 최초이자 유일한 HER2 표적 항체-약물 접합체(ADC)입니다.

또한, 2023년 4월, HUTCHMED (China) Limited는 중국 국가약품감독관리국(NMPA)에 진행성 위암 또는 위식도 접합부 선암의 2차 치료를 위한 프루퀸티닙과 파클리탁셀 병용요법에 대한 신약 허가 신청(NDA)을 접수하여 심사에 들어갔습니다.
증가하는 신약 파이프라인
다양한 바이오 및 제약 회사들이 파이프라인에 여러 신약을 개발하고 있습니다. CNBG-Virogin Biotech, Minneamrita Therapeutics LLC 등의 회사들은 위암 치료에 대한 안전성과 효능을 시험하고 있습니다. 병용 요법은 환자에게 투여하여 치료 효과를 관찰하고 있습니다.
저장성 암 병원은 CSPC Ouyi Pharmaceutical Co., Ltd.와 함께 3기 위암 환자를 대상으로 알부민 결합 파클리탁셀과 S-1 병용요법과 옥살리플라틴과 카페시타빈(XELOX) 병용요법의 효능 및 안전성을 비교하는 3상 임상시험을 보조 요법으로 진행하고 있습니다. 예상 완료일은 2024년 10월 31일입니다.
방사선 치료 및 화학 요법 관련 합병증
화학 요법과 방사선 치료는 위암의 주요 치료법입니다. 화학 요법은 햇빛에 대한 민감성 증가 및 일광 화상 위험 증가와 같은 부작용을 유발할 수 있습니다. 또한 화학 요법으로 인해 일시적으로 유당 불내증이 발생할 수 있습니다. 위암에 대한 화학 요법과 방사선 치료 모두 설사, 메스꺼움, 구토를 유발할 수 있습니다. 골반 부위 방사선 조사와 일부 항암제는 요로 감염(UTI)을 유발할 수 있습니다. 위암 치료 외에도 에스트로겐 수치를 감소시켜 질 건조증, 원발성 난소 기능 부전, 테스토스테론 수치 및 정자 수 감소와 같은 증상을 유발할 수 있습니다.
세분화 분석
전 세계 위암 치료 시장은 암 유형, 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.

화학요법 부문은 시장 점유율의 약 XX%를 차지했습니다.
화학요법은 위를 넘어 전이된 암세포를 표적으로 삼거나 수술 전 종양 크기를 줄여 진행성 위암 환자의 증상을 완화할 수 있습니다. 위암 치료에서 화학요법의 사용은 빠르게 발전하고 있으며, 최적의 치료 전략은 종양의 분자적 특성, 암의 병기 및 기타 개별 요인에 따라 달라질 수 있습니다.
위암 치료에 화학요법 사용이 증가함에 따라 시장에 출시되는 화학요법 제품도 증가하고 있습니다. 예를 들어, 2022년 4월 BDR Pharmaceuticals는 진행성 위암 치료를 위한 제네릭 경구 약물인 푸르메실(Furmecil)을 출시했습니다.
또한, 2023년 6월 머크앤컴퍼니(Merck & Co.)의 키트루다(Keytruda)는 새로운 3상 임상시험에서 키트루다와 화학요법 병용 투여가 진행성 또는 전이성 HER2 음성 위암 또는 위식도 접합부암 환자에서 화학요법 단독 투여에 비해 환자의 생존 기간을 유의미하게 연장시키는 것으로 나타났습니다. 키트루다 병용 요법은 사망 위험을 22% 감소시켰습니다.
지역 분석
북미는 2022년 시장 점유율의 약 XX%를 차지했습니다.
북미는 위암 치료 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 미국 암 협회(American Cancer Society)는 2023년 미국에서 약 26,500건의 위암(남성 15,930건, 여성 10,570건)이 새로 발생할 것으로 추정했습니다.
또한, 부적절한 식습관과 흡연과 같은 생활 습관 요인도 위암의 원인이 됩니다. 소금, 훈제 또는 절인 식품을 많이 섭취하고 과일과 채소를 적게 먹는 식단은 위암 발병 위험을 높이는 것으로 알려져 있습니다. 마찬가지로, 흡연은 위암의 가장 흔한 위험 요인이며, 북미 여러 국가에서 흡연율이 여전히 높습니다. 이러한 모든 요인들이 예측 기간 동안 북미 위암 시장의 성장을 촉진할 것으로 예상됩니다.

COVID-19 영향 분석
COVID-19 팬데믹은 2차 진료에도 막대한 영향을 미쳤습니다. 병원과 보건소는 정부 지침에 따라 사회적 거리두기 조치를 유지하기 위해 운영 역량을 축소했고, 그 결과 암 진단이 지연되었습니다. 2021년 3월 보고서에 따르면 팬데믹 기간 동안 새로운 종양학 임상 시험이 60% 감소하여 새로운 암 치료법 개발이 둔화될 것이라는 우려가 커졌습니다. 영국의 주요 암 연구 자선 단체인 Cancer Research UK는 위암을 포함한 암 환자를 보호하고 임상 연구 인력을 COVID-19 최전선 의료 서비스 지원에 재배치하기 위해 임상 시험의 95%에서 모집을 중단했습니다.

유형별
• 선암
• 위장관 기질종양(GIST)
• 유암종
• 림프종
• 기타
치료 유형별
• 수술
o 내시경적 점막 절제술
o 위 절제술
• 부분 절제술
• 전체 절제술
o 내강 스텐트 삽입술
o 내강 레이저 치료
o 위공장문합술
• 방사선 치료
• 화학 요법
o 카페시타빈
o 시스플라틴
o 도세탁셀
o 옥살리플라틴
o 파클리탁셀
o 고온 복강 내 화학 요법(HIPEC)
o 기타
• 표적 치료
o 라무시루맙
o 레고라페닙
o 트라스투주맙
• 면역 요법
o 니볼루맙
o 펨브롤리주맙
• 기타
유통 채널별
• 병원 및 클리닉
• 암 센터
• 암 연구 기관
• 기타
By 지역
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2022년 2월, 오노 제약(주)과 브리스톨-마이어스 스큅은 일본 교토에 위치한 프라임 리서치 인스티튜트 포 메디컬 RWD(Prime Research Institute for Medical RWD, Inc.)와 위암 환자를 대상으로 옵디보(Opdivo)와 화학요법 병용 투여에 대한 대규모 다기관 임상 연구를 위탁하는 계약을 체결했습니다.

• 2023년 2월, 아스트라제네카는 키메드 바이오사이언스(Keymed Biosciences)와 레푸 바이오파마(Lepu Biopharma) 계열사가 설립한 합작 회사인 KYM 바이오사이언스(KYM Biosciences)와 글로벌 독점 라이선스 계약을 체결했습니다. 이번 거래는 현재 위암 치료제로 평가 중인 항체-약물 접합체(ADC)인 CMG901을 중심으로 이루어졌습니다.
• 2022년 11월, 글로벌 여성 건강 기업인 오르가논(Organon)은 허셉틴(Herceptin)의 바이오시밀러인 온트루잔트(ONTRUZANT)의 출시 및 유통을 발표하여, 조기 유방암(EBC), 전이성 유방암(MBC) 및 전이성 위암 진단을 받은 캐나다 성인 환자들에게 추가적인 치료 옵션을 제공했습니다.
경쟁 환경
위암 치료 시장의 주요 글로벌 업체로는 머크앤컴퍼니(Merck & Co., Inc), 브리스톨마이어스스큅(Bristol-Myers Squibb), 어코드헬스케어(Accord Healthcare), 사노피(Sanofi S.A), 바이엘파마(Bayer Pharma AG), 일라이릴리앤컴퍼니(Eli Lilly and Company), 테바제약(Teva Pharmaceutical Industries Ltd), 셀트리온(Celltrion, Inc.), 제넨텍(Genentech, Inc.), 윈스럽미국(Winthrop US) 등이 있습니다.
보고서 구매 이유

• 암 유형, 치료 유형, 최종 사용자 및 지역별 글로벌 위암 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 위암 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 위암 치료 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Stomach Cancer Treatment Market reached US$ 4.7 billion in 2022 and is expected to reach US$ 10.3 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.
Stomach cancer is a disease in which malignant (cancer) cells are formed in the stomach lining. Stomach cancer usually begins in the mucus-producing cells that line the stomach. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. Most people typically do not show signs in the earlier stages due to which diagnosis becomes difficult. Because of this, it often goes undiagnosed until after it spreads to other body parts and cause metastasis.
Gastric cancer is the third leading cause of death throughout the world. According to the National Cancer Institute, 1.8% of the deaths caused by cancer are due to stomach cancer. According to the American Cancer Society estimate in 2022, stomach cancer accounts for about 1.5% of all new cancers in the U.S. annually.
Furthermore, the rising incidence of gastric cancer, the adoption of a sedentary lifestyle and irregular food habits, and rising research and development in the oncology sector are a few factors that are expected to drive the market in the forthcoming period.
Dynamics
Increasing Product Launches
Gastric cancer is currently the fifth most frequently diagnosed cancer and the fourth leading cancer-related cause of death worldwide. Over 90-95% of cases are classified as adenocarcinoma. The American Cancer Society’s 2022 estimates include 26,380 new cases and 11,090 deaths from gastric cancer.
For instance, in February 2023, Enhertu launched gastric cancer tertiary treatment in South Korea. The first and only HER2 target ADC, which improves treatment for advanced and metastatic gastric cancer.
Additionally, in April 2023, HUTCHMED (China) Limited was granted a New Drug Application (“NDA”) for fruquintinib along with paclitaxel for the treatment of second-line progressive gastric or gastroesophageal junction adenocarcinoma in China was accepted for consideration by the China National Medical Products Administration (“NMPA”).
Increasing Drug Pipeline
Various biotech and pharmaceutical companies are developing various drugs which are in the pipeline. Companies like CNBG-Virogin Biotech, Minneamrita Therapeutics LLC, etc. These drugs are tested for safety and efficacy in treating gastric cancer. Combination drugs are given to the patients to observe the effectiveness of the therapy.
Zhejiang Cancer Hospital along with CSPC Ouyi Pharmaceutical Co., Ltd. are conducting a phase 3 clinical trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage 3 gastric cancer as adjuvant setting. The estimated completion date is October 31, 2024.
Complications Related to Radiotherapy and Chemotherapy
Chemotherapy and radiotherapy are the leading treatments for stomach cancer. Chemotherapy may also lead to implications such as sunlight sensitivity and increasing sunburn risk. Chemotherapy can cause individuals to become temporarily lactose intolerant. Both chemotherapy and radiation therapy for stomach cancer can cause diarrhea, nausea, and vomiting. Radiation toward the pelvis and some chemotherapy drugs lead to urinary tract infections (UTIs). Apart from treating stomach cancer, it can decrease estrogen levels, causing symptoms like vaginal dryness and conditions like primary ovarian insufficiency, testosterone levels, and sperm count.
Segment Analysis
The global stomach cancer treatment market is segmented based on cancer type, treatment type, end-user, and region.
The Chemotherapy Segment Accounted for Approximately XX% of the Market Share
Chemotherapy can target cancer cells that have spread beyond the stomach or shrink the tumor before surgery and alleviate symptoms in advanced cases of gastric cancer. The use of chemotherapy in gastric cancer is rapidly evolving, and the optimal treatment strategy may vary depending on the tumor's molecular characteristics, the stage of cancer, and other individual factors.
Due to the increased use of chemotherapy treatment for stomach cancer, there is an increase in chemotherapeutic products in the market. For instance, in April 2022, BDR Pharmaceuticals launched Furmecil, a generic oral drug for treating advanced gastric cancer.
Furthermore, in June 2023, Merck & Co.’s Keytruda, in a new phase 3 trial, Keytruda plus chemotherapy, significantly extended patients’ lives over chemo alone in newly diagnosed HER2-negative gastric or gastroesophageal junction cancers that are advanced or metastatic. The Keytruda combination cut the risk of death by 22%.
Geographical Analysis
North America accounted for Approximately XX% of the Market Share in 2022
North America accounts for the largest market share for stomach cancer treatment. The American Cancer Society's estimates for stomach cancer (also known as gastric cancer) in the United States for 2023 are about 26,500 new cases of stomach cancer (15,930 in men and 10,570 in women).
In addition to that, lifestyle factors such as improper diet and smoking cause gastric cancer. Diets high in salt, smoked or pickled foods, and low in fruits and vegetables have been linked to an increase in the risk of gastric cancer. Similarly, smoking is a most common risk factor for gastric cancer and the prevalence of smoking in many countries in North America remains high. All these factors are anticipated to boost the growth of the North American gastric cancer market during the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has also had a massive impact on secondary care. Hospitals and health centers reduced their functioning capacity to maintain social distancing measures by government guidelines, which consequently delayed cancer diagnosis. A March 2021 report noted a 60% decrease in new oncology clinical trials during the pandemic, fueling concerns regarding slowing the development of new cancer therapies. A major UK-based cancer research charity, Cancer Research UK, halted recruitment in 95% of their clinical trials to protect cancer patients including stomach cancer, and cope with the redeployment of clinical research staff to support frontline COVID-19-facing healthcare services.
By Type
• Adenocarcinoma
• Gastrointestinal stromal tumors (GIST)
• Carcinoid tumors
• Lymphoma
• Others
By Treatment Type
• Surgery
o Endoscopic mucosal resection
o Gastrectomy
• Subtotal
• Total
o Endoluminal stent placement
o Endoluminal laser therapy
o Gastrojejunostomy
• Radiation therapy
• Chemotherapy
o Capecitabine
o Cisplatin
o Docetaxel
o Oxaliplatin
o Paclitaxel
o Hyperthermic intraperitoneal chemotherapy (HIPEC)
o Others
• Targeted therapy
o Ramucirumab
o Regorafenib
o Trastuzumab
• Immunotherapy
o Nivolumab
o Pembrolizumab
• Others
By Distribution Channel
• Hospitals and Clinics
• Cancer Centers
• Cancer Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb signed an outsourcing agreement with Prime Research Institute for Medical RWD, Inc. Kyoto, Japan, an industry-sponsored, large-scale, multi-institutional clinical research in patients with gastric cancer treated with Opdivo in combination with chemotherapy.
• In February 2023, AstraZeneca signed a global exclusive license agreement deal with KYM Biosciences, a joint venture established by affiliates of Keymed Biosciences and Lepu Biopharma. The deal is centered around CMG901, an antibody-drug conjugate (ADC) currently being evaluated as a potential treatment for gastric cancer.
• In November 2022, Organon, a global women’s health company, declared the availability and distribution of ONTRUZANT, a biosimilar of Herceptin, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer.
Competitive Landscape
The major global players in the stomach cancer treatment market include Merck & Co., Inc, Bristol-Myers Squibb, Accord Healthcare, Sanofi S.A, Bayer Pharma AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Celltrion, Inc., Genentech, Inc., and Winthrop US among others.
Why Purchase the Report?
• To visualize the global stomach cancer treatment market segmentation based on cancer type, treatment type, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of stomach cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global stomach cancer treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Treatment Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Product Launches
4.1.1.2. Increasing Drug Pipeline
4.1.2. Restraints
4.1.2.1. Complications Related to Radiotherapy and Chemotherapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Cancer Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Adenocarcinoma
7.3. Gastrointestinal stromal tumors (GIST)
7.4. Carcinoid tumors
7.5. Lymphoma
7.6. Others
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Surgery
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Endoscopic mucosal resection
8.2.4. Gastrectomy
8.2.5. Endoluminal stent placement
8.2.6. Endoluminal laser therapy
8.2.7. Gastrojejunostomy
8.3. Radiation therapy
8.4. Chemotherapy
8.4.1. Capecitabine
8.4.2. Cisplatin
8.4.3. Docetaxel
8.4.4. Oxaliplatin
8.4.5. Paclitaxel
8.4.6. Others
8.5. Targeted therapy
8.5.1. Ramucirumab
8.5.2. Regorafenib
8.5.3. Trastuzumab
8.5.4. Others
8.6. Immunotherapy
8.6.1. Nivolumab
8.6.2. Pembrolizumab
8.6.3. Hyperthermic intraperitoneal chemotherapy (HIPEC)
8.6.4. Others
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital and Clinics
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Care Centers
9.4. Cancer Research Institutes
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck & Co.
12.1.1. Company Overview
12.1.2. Type Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Bristol-Myers Squibb
12.3. Accord Healthcare
12.4. Sanofi S.A.
12.5. Bayer Pharma AG
12.6. Eli Lilly and Company
12.7. Teva Pharmaceuticals Industries, Ltd.
12.8. Celltrion, Inc.
12.9. Genentech, Inc.
12.10. Winthrop US
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck & Co., 4.	Key Developments, Bristol-Myers Squibb, Accord Healthcare, Sanofi S.A., Bayer Pharma AG, Eli Lilly and Company, Teva Pharmaceuticals Industries, Ltd., Celltrion, Inc., Genentech, Inc., Winthrop US

표 목록 (Tables)

List of Tables

Table 1 Global Stomach Cancer Treatment Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Stomach Cancer Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Stomach Cancer Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Stomach Cancer Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Stomach Cancer Treatment Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 7 Global Stomach Cancer Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Billion)

Table 8 Global Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 9 Global Stomach Cancer Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 10 Global Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 11 Global Stomach Cancer Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 12 Global Stomach Cancer Treatment Market Value, By Region, 2022-2031 (US$ Billion)

Table 13 North America Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 14 North America Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 15 North America Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 16 North America Stomach Cancer Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 17 South America Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 18 South America Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 19 South America Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 20 South America Stomach Cancer Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 Europe Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 22 Europe Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 23 Europe Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 24 Europe Stomach Cancer Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 25 Asia-Pacific Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 26 Asia-Pacific Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 27 Asia-Pacific Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 28 Asia-Pacific Stomach Cancer Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 29 Middle East & Africa Stomach Cancer Treatment Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 30 Middle East & Africa Stomach Cancer Treatment Market Value, By Treatment Type, 2022-2031 (US$ Billion)

Table 31 Middle East & Africa Stomach Cancer Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 32 Merck & Co: Overview

Table 33 Merck & Co: Product Portfolio

Table 34 Merck & Co: Key Developments

Table 35 Bristol-Myers Squibb: Overview

Table 36 Bristol-Myers Squibb: Product Portfolio

Table 37 Bristol-Myers Squibb: Key Developments

Table 38 Accord Healthcare: Overview

Table 39 Accord Healthcare: Product Portfolio

Table 40 Accord Healthcare: Key Developments

Table 41 Sanofi S.A.: Overview

Table 42 Sanofi S.A.: Product Portfolio

Table 43 Sanofi S.A.: Key Developments

Table 44 Bayer Pharma AG: Overview

Table 45 Bayer Pharma AG: Product Portfolio

Table 46 Bayer Pharma AG: Key Developments

Table 47 Eli Lilly and Company: Overview

Table 48 Eli Lilly and Company: Product Portfolio

Table 49 Eli Lilly and Company: Key Developments

Table 50 Teva Pharmaceuticals Industries, Ltd.: Overview

Table 51 Teva Pharmaceuticals Industries, Ltd.: Product Portfolio

Table 52 Teva Pharmaceuticals Industries, Ltd.: Key Developments

Table 53 Celltrion, Inc.: Overview

Table 54 Celltrion, Inc.: Product Portfolio

Table 55 Celltrion, Inc.: Key Developments

Table 56 Genentech, Inc.: Overview

Table 57 Genentech, Inc.: Product Portfolio

Table 58 Genentech, Inc.: Key Developments

Table 59 Winthrop US: Overview

Table 60 Winthrop US: Product Portfolio

Table 61 Winthrop US: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 3 Global Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 4 Global Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Stomach Cancer Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Stomach Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2022-2031 (%)

Figure 7 Adenocarcinoma Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 8 Gastrointestinal stromal tumors (GIST) Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 9 Carcinoid tumors Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 10 Lymphoma Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 11 Others Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 12 Global Stomach Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2031 (%)

Figure 13 Surgery Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 14 Radiation therapy Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 15 Chemotherapy Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 16 Targeted therapy Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 17 Immunotherapy Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 18 Others Treatment Type in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 19 Global Stomach Cancer Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 20 Hospitals and Clinics in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 21 Cancer Care Centers in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 22 Cancer Research Institutes in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 23 Others in Global Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 24 Global Stomach Cancer Treatment Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 25 North America Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 26 Asia-Pacific Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 27 Europe Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 28 South America Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 29 Middle East and Africa Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 30 North America Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 31 North America Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 32 North America Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 33 North America Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 34 North America Stomach Cancer Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 35 South America Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 36 South America Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 37 South America Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 38 South America Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 39 South America Stomach Cancer Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 40 Europe Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 41 Europe Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 42 Europe Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 43 Europe Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 44 Europe Stomach Cancer Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 45 Asia-Pacific Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 46 Asia-Pacific Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 47 Asia-Pacific Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 48 Asia-Pacific Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 Asia-Pacific Stomach Cancer Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 50 Middle East & Africa Stomach Cancer Treatment Market Value, 2022-2031 (US$ Billion)

Figure 51 Middle East & Africa Stomach Cancer Treatment Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 52 Middle East & Africa Stomach Cancer Treatment Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 53 Middle East & Africa Stomach Cancer Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 54 Merck & Co: Financials

Figure 55 Bristol-Myers Squibb: Financials

Figure 56 Accord Healthcare: Financials

Figure 57 Sanofi S.A.: Financials

Figure 58 Bayer Pharma AG: Financials

Figure 59 Eli Lilly and Company: Financials

Figure 60 Teva Pharmaceuticals Industries, Ltd.: Financials

Figure 61 Celltrion, Inc.: Financials

Figure 62 Genentech, Inc.: Financials

Figure 63 Winthrop US: Financials

세계 위암 치료 시장 – 2023-2030

Global Stomach Cancer Treatment Market - 2023-2030